Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.
We used three to six courses of 2-chlorodeoxyadenosine (2-CdA) (2-h infusion at 0.14 mg/kg per day x 5 days) given over a period of 3-36 months to treat four patients with aggressive systemic mast cell disease (SMCD) that was resistant to interferon-alpha (IFN-alpha). Treatment with 2-CdA resulted in a major response in two patients and a good partial response in one other patient (75% overall response). Treatment was well tolerated and duration of remission in responding patients ranges from 2 months to 4+ years since the completion of treatment with 2-CdA.
Pardanani
A
A
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Hoffbrand
A V
AV
Butterfield
J H
JH
Tefferi
A
A
D000328:Adult; D000368:Aged; D001856:Bone Marrow Examination; D017338:Cladribine / Q000008:administration & dosage* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D008297:Male; D008415:Mastocytosis / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome
D016898:Interferon-alpha; D017338:Cladribine